ArticlePloS one2013
Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05723601 (Addressing Preference as a Patient-centered Outcome to Prevent Recurrent Urinary Tract Infection), which is not on this map. Cited by 319 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Addressing Preference as a Patient-centered Outcome to Prevent Recurrent Urinary Tract Infection (rUTI) in Post-menopausal Women: a Cross-over Randomized Controlled Trial
Who cites it
319 citing papers in PubMed, 4 syntheses or guidelines pooled it, 541 citations in OpenAlex.
- Risk of HSV-2 Acquisition Among Women with Bacterial Vaginosis: Systematic Review and Meta-Analysis.Viruses · 2026Pooled it
- Microbiota composition of the female reproductive tract and miscarriage: a systematic review and meta-analysis.NPJ biofilms and microbiomes · 2026Pooled it
- The Effect of Exogenous Sex Steroids on the Vaginal Microbiota: A Systematic Review.Frontiers in cellular and infection microbiology · 2021Pooled it
- Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.PloS one · 2021Pooled it
- Adjunct vaginal lactic acid with single-dose metronidazole for bacterial vaginosis: a randomized controlled trial.BMC women's health · 2026Trial
- Impact of vaginal microbiota on the clinical efficacy and long-term recurrence of ketoconazole suppositories in treating severe vulvovaginal candidiasis: a secondary analysis of a multicentre randomised trial.Frontiers in cellular and infection microbiology · 2025Trial
- Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.mSphere · 2023Trial
- 3D cell assemblies for controlled evaluation of response to dual agent delivery nanofibers targeting bacterial vaginosis.Biomaterials advances · 2026Article
- Association Between Vaginal Microbiota and Female Infertility: A Systematic Review and Meta-Analysis.Microorganisms · 2026Review
- Antimicrobial and probiotic potential of Lactobacillus from traditional dairy products against uropathogenic gram-negative bacteria.Antonie van Leeuwenhoek · 2026Article
- The redefined identity ofJournal of bacteriology · 2026Review
- The Impact of the Vaginal Microbiome and Microbial Metabolites on HIV Transmission at the Female Reproductive Tract Epithelial Barrier.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Elucidating the Staphylococcus aureus TSST-1 Regulatory Network as a Response to Vaginal pH.Molecular microbiology · 2026Article
- Complement protein concentrations and activity in human cervical mucus.bioRxiv : the preprint server for biology · 2026Article
- Rethinking Vaginal Microbiome Resilience: A Conceptual Multi-Omic Framework.Microorganisms · 2026Review
- Matriptase proteolysis selectively drives disassembly and internalization of the claudin-7 complex while preserving E-cadherin.Human cell · 2026Article
- Harnessing mucosal immunity for protective vaccines.Nature reviews. Immunology · 2026Review
- Electrospun nanofibers for antibiotic and probiotic co-delivery to target bacterial vaginosis.International journal of pharmaceutics · 2026Article
- Bidirectional Interactions Between Cervicovaginal Microbiota and Human Papillomavirus Drive Persistence and Disease Progression.International journal of molecular sciences · 2026Review
- Multiomic analysis reveals that polyamines alter G. vaginalis-induced cervicovaginal epithelial cell dysfunction.Research square · 2026Article
259 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Lactic acid at sufficiently acidic pH is a potent microbicide, and lactic acid produced by vaginal lactobacilli may help protect against reproductive tract infections. However, previous observations likely underestimated healthy vaginal acidity and total lactate concentration since they failed to exclude women without a lactobacillus-dominated vaginal microbiota, and also did not account for the high carbon dioxide, low oxygen environment of the vagina. Fifty-six women with low (0-3) Nugent scores (indicating a lactobacillus-dominated vaginal microbiota) and no symptoms of reproductive tract disease or infection, provided a total of 64 cervicovaginal fluid samples using a collection method that avoided the need for sample dilution and rigorously minimized aerobic exposure. The pH of samples was measured by microelectrode immediately after collection and under a physiological vaginal concentration of CO2. Commercial enzymatic assays of total lactate and total acetate concentrations were validated for use in CVF, and compared to the more usual HPLC method. The average pH of the CVF samples was 3.5 ± 0.3 (mean ± SD), range 2.8-4.2, and the average total lactate was 1.0% ± 0.2% w/v; this is a five-fold higher average hydrogen ion concentration (lower pH) and a fivefold higher total lactate concentration than in the prior literature. The microbicidal form of lactic acid (protonated lactic acid) was therefore eleven-fold more concentrated, and a markedly more potent microbicide, than indicated by prior research. This suggests that when lactobacilli dominate the vaginal microbiota, women have significantly more lactic acid-mediated protection against infections than currently believed. Our results invite further evaluations of the prophylactic and therapeutic actions of vaginal lactic acid, whether provided in situ by endogenous lactobacilli, by probiotic lactobacilli, or by products that reinforce vaginal lactic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.